hVIVO plc (LON:HVO - Get Free Report)'s share price passed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of GBX 16.22 ($0.22) and traded as high as GBX 17.25 ($0.23). hVIVO shares last traded at GBX 16.90 ($0.23), with a volume of 814,089 shares trading hands.
Analyst Upgrades and Downgrades
Separately, Shore Capital reissued a "buy" rating on shares of hVIVO in a report on Thursday, April 10th.
View Our Latest Stock Report on HVO
hVIVO Trading Down 1.6%
The firm has a 50 day moving average of GBX 16.28 and a 200-day moving average of GBX 18.36. The firm has a market capitalization of £111.44 million, a P/E ratio of 6.50 and a beta of 0.97. The company has a quick ratio of 1.16, a current ratio of 1.61 and a debt-to-equity ratio of 33.86.
hVIVO (LON:HVO - Get Free Report) last issued its earnings results on Thursday, April 10th. The company reported GBX 1.69 ($0.02) EPS for the quarter. hVIVO had a net margin of 25.96% and a return on equity of 47.93%. On average, equities research analysts predict that hVIVO plc will post 1.5492958 earnings per share for the current fiscal year.
Insider Buying and Selling at hVIVO
In other hVIVO news, insider Yamin Mo' Khan sold 3,062,246 shares of the company's stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of GBX 17 ($0.23), for a total value of £520,581.82 ($703,488.95). Corporate insiders own 14.03% of the company's stock.
About hVIVO
(
Get Free Report)
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.
Featured Articles
Before you consider hVIVO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and hVIVO wasn't on the list.
While hVIVO currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
